Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.33 |
| ▸ | HMGCR | P04035 | 4/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697418 | 0.88 | — | — | |
| SCHEMBL7064860 | 0.76 | TSHR (0.34) | TSHR | |
| SCHEMBL157189 | 0.75 | — | — | |
| SCHEMBL3040799 | 0.75 | TSHR (0.37) | TSHR | |
| SCHEMBL2120698 | 0.74 | PTPN7 (0.38) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL9514818 | 0.73 | PTPN7 (0.50) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL9515428 | 0.73 | PTPN7 (0.50) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL154494 | 0.73 | PTPN7 (0.50) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL3866734 | 0.73 | PTPN7 (0.50) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL1117101 | 0.73 | PTPN7 (0.50) | TSHRPTPN7HMGCRRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES LLC (US) | 2016-10-20 | — | — | US | disclosed |
| US-9346845-B2 | Anionic conjugates of glycosylated bacterial metabolite | GLYCAN BIOSCIENCES LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | Glycosynnovations Pty Ltd (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8791245-B2 | Anionic conjugates of glycosylated bacterial metabolite | Glycan Bioscience LLC (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2421877-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | Glycan Biosciences Pty Ltd (AU) | 2012-02-29 | — | — | EP | disclosed |
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-04 | — | — | US | disclosed |
| WO-2010037179-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2010-04-08 | — | — | WO | disclosed |
| US-7205333-B2 | Therapy for influenza virus; inhaler | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-04-17 | — | — | US | disclosed |
| US-7101909-B2 | Compound of a ligand of 2-methoxy methylester-6-fluoronaphthalene, an aryl ligand and a linker; each ligand domain capable of binding to a Ca++ channel | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064038-A1 | NOVEL ANALGESIC AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064051-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999051565-A9 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE INC (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999051565-A1 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | TSHR 3687/4885PTPN7 1465/4885HMGCR 2793/4885 |
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | TSHR 3687/4885PTPN7 1465/4885HMGCR 2793/4885 |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | GNE, CD44, FUT5 | TSHR 3687/4885PTPN7 1465/4885HMGCR 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.